U.S. markets close in 6 hours 25 minutes
  • S&P 500

    3,801.53
    +33.06 (+0.88%)
     
  • Dow 30

    31,238.29
    +314.15 (+1.02%)
     
  • Nasdaq

    12,803.10
    +79.63 (+0.63%)
     
  • Russell 2000

    2,146.92
    -60.87 (-2.76%)
     
  • Crude Oil

    65.64
    +1.81 (+2.84%)
     
  • Gold

    1,701.60
    +0.90 (+0.05%)
     
  • Silver

    25.39
    -0.08 (-0.30%)
     
  • EUR/USD

    1.1930
    -0.0049 (-0.41%)
     
  • 10-Yr Bond

    1.5730
    +0.0230 (+1.48%)
     
  • GBP/USD

    1.3854
    -0.0040 (-0.29%)
     
  • USD/JPY

    108.3090
    +0.3330 (+0.31%)
     
  • BTC-USD

    48,597.71
    -835.86 (-1.69%)
     
  • CMC Crypto 200

    972.09
    +28.92 (+3.07%)
     
  • FTSE 100

    6,710.21
    +59.33 (+0.89%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Soligenix, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agents (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at brittney@investorsummitgroup.com

SOURCE: Soligenix, Inc.



View source version on accesswire.com:
https://www.accesswire.com/615982/Soligenix-Inc-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th